We recently developed a simple and fast assay technique, providing the possibility of monitoring of @entity1363 (M) during sedation. We compared HPLC vs FPIA for the measurement of the sum M plus alpha @entity30532 (OM), its main and pharmacologically active metabolite, in the serum of sedated ICU @entity1 ; this activity referred to as M-like. We identified certain @entity1 in whom M-like activity appeared abnormally high in comparison with HPLC assays. Their common denominators were: long-term sedation with M, and seriously @entity8 . Further, the conjugates of OM (OMG) accumulated in @entity1 with @entity810 could contribute to the sedation. We compared the metabolic and analytic behavior of M, OM, and OMG in 2 groups of sedated @entity1 either presenting with normal renal functions (group 1) or with a picture of @entity810 (group 2). Blood samples were assayed by HPLC and by FPIA and analysis was performed before and after hydrolysis of OMG. Before hydrolysis there was a dramatic accumulation of OMG in the @entity1 of group 2, HPLC vs FPIA results were not different within group 1, while in group 2 the FPIA response exceeded that of HPLC. After hydrolysis, measurement by HPLC was greatly increased in group 2, in each group (vs HPLC) and from one group to another, the FPIA signal (the M-like activity) showed a significant increase. It would be important to take OMG into account as a coprotagonist in sedation whenever circumstances predispose to its accumulation.

Influence of @entity810 on FPIA rapid serum assay of XXXX and its main metabolite.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity8 :: ('MESH:D007674', 'Disease') :: ['impaired renal function'] @entity810 :: ('MESH:D058186', 'Disease') :: ['acute renal failure'] @entity30532 :: ('MESH:C040081', 'Chemical') :: ['1-hydroxymidazolam'] @entity1363 :: ('MESH:D008874', 'Chemical') :: ['midazolam']
@entity1363 :: (MESH:D008874,Chemical) :: ['midazolam']
